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Abstract
Background: Increasing evidence suggests that individual isoforms of protein kinase C (PKC) play distinct roles in regulating
platelet activation.
Methodology/Principal Findings: In this study, we focus on the role of two novel PKC isoforms, PKCd and PKCe, in both
mouse and human platelets. PKCd is robustly expressed in human platelets and undergoes transient tyrosine
phosphorylation upon stimulation by thrombin or the collagen receptor, GPVI, which becomes sustained in the presence
of the pan-PKC inhibitor, Ro 31-8220. In mouse platelets, however, PKCd undergoes sustained tyrosine phosphorylation
upon activation. In contrast the related isoform, PKCe, is expressed at high levels in mouse but not human platelets. There is
a marked inhibition in aggregation and dense granule secretion to low concentrations of GPVI agonists in mouse platelets
lacking PKCe in contrast to a minor inhibition in response to G protein-coupled receptor agonists. This reduction is
mediated by inhibition of tyrosine phosphorylation of the FcRc-chain and downstream proteins, an effect also observed in
wild-type mouse platelets in the presence of a PKC inhibitor.
Conclusions: These results demonstrate a reciprocal relationship in levels of the novel PKC isoforms d and e in human and
mouse platelets and a selective role for PKCe in signalling through GPVI.
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Introduction
The major receptors which induce platelet activation signal by
different mechanisms although many converge on the activation of
the protein kinase C (PKC) family of serine/threonine kinases. For
example, thrombin signals through heterotrimeric Gq proteins
leading to activation of phospholipase C (PLC)b isoforms, while
the collagen receptor GPVI activates a distinct isoform, PLCc2,
through an immunoreceptor tyrosine-based activation motif
(ITAM)-dependent pathway, involving sequential activation of
Src, Syk and Tec family tyrosine kinases [1]. PLCb and c isoforms
hydrolyse phosphatidylinositol 4,5-bisphosphate to generate the
second messengers inositol 1,4,5-trisphosphate (IP3) and 1,2-
diacylglycerol which mobilise Ca
2+ from intracellular stores and
activate classical and novel isoforms of PKC [2]. PKCs play a
critical role in platelet activation as pharmacological inhibitors of
PKC inhibit aggregation and secretion by the majority of agonists
[3,4]. Many PKC substrates have been identified in platelets
including components of the secretory machinery and signalling
molecules [5,6,7,8].
PKC consists of nine structurally related isoforms, sub-divided
into three groups based on mechanism of activation and structural
similarities [9]. The classical PKC isoforms (a, b, c), contain
domains conferring regulation to diacylglycerol and Ca
2+ and
require both for full activation. The novel isoforms (d, e, h, g) are
Ca
2+-independent whereas the atypical isoforms i ˜/l and f are not
directly regulated by diacylglycerol or Ca
2+. Initial evidence for
the involvement of the novel PKC isoforms in platelet activation
came from studies monitoring tyrosine phosphorylation of these
proteins following stimulation of human platelets. PKCd is
tyrosine phosphorylated at two distinct sites, Tyr311 and 565, in
response to activation of GPVI and PAR receptors, but not by the
major platelet integrin, aIIbb3 [10,11,12,13]. This provides a
potential mechanism for both direct regulation of PKCd activity
and in initiating downstream signalling through recruitment of
SH2 domain containing proteins. PKCh is tyrosine phosphorylat-
ed in human platelets in response to collagen, the snake toxin
Alboaggregin A (which interacts with both GPVI and GP-Ib-IX-
V) and downstream of aIIbb3 [14,15]. PKCe has also been
reported to be tyrosine phosphorylated downstream of Alboag-
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unable to detect its expression in human platelets [16].
Further evidence for different functions of individual PKC
isoforms downstream of different receptors relied on inhibitors
with preferential isoform specificity in vitro [11,17]. However the
selectivity of these inhibitors within a cell remains unclear and
many have been shown to have additional effects, including the so-
called selective PKCd inhibitor, rottlerlin [18,19]. More recently,
studies of platelets derived from mice lacking individual PKC
isoforms have proven invaluable in providing information about
specific roles of individual isoforms. Platelets deficient in PKCb or
PKCh both show a deficiency in spreading on immobilised
fibrinogen, consistent with a role for these isoforms in mediating
signals induced by aIIbb3 [15,16]. In contrast, mouse platelets
lacking PKCd show enhanced aggregation and spreading when
stimulated by collagen, suggesting a feedback inhibitory role [20].
The present study focuses on two novel isoforms, PKCd and
PKCe, in mouse and human platelets. Unexpectedly, we observed
a reciprocal relationship in expression, with PKCd detected at
high and low levels in human and mouse platelets, respectively,
and vice versa for PKCe. We reveal a novel role for PKCe in
aggregation to collagen, but not to G protein-coupled receptor
agonists, mediated through tyrosine phosphorylation of FcRc-
chain.
Methods
Reagents
Anti-PKCe (clone 21) and h antibodies were purchased from
BD Pharmingen (Oxford, UK) and anti-PKCg from Santa Cruz
Biotechnology, Inc. (CA, USA). Anti-PKCd antibodies were from
BD Pharmingen (Oxford, UK) (clone 14) and Santa Cruz
Biotechnology, Inc. (CA, USA) (sc-937) used for western blotting
and immunoprecipitation, respectively. Polyclonal antibodies to
PLCc2 (DN84), Syk (BR15) and Btk (BL7) were kindly provided
by Dr Mike Tomlinson (formerly of DNAX Research Institute,
Palo Alto, CA, USA). PKCe2deficient mice [21] were bred as
heterozygotes on a B6 background and all results compared to
wild type litter-matched controls. P-PACK (D-Phe-Pro-Arg-
chloromethylketone, HCl) and AEBSF were from Merck Biosci-
ences Ltd (Nottingham, UK). Fibrillar horm collagen from equine
tendon was purchased from Nycomed (Linz, Austria). Horm
collagen is a preparation of native collagen fibrils from equine
tendon which mainly contains predominantly type I collagen
[22,23]. Other reagents were from Sigma (Poole, UK), or
previously described sources [24,25,26].
Human and mouse platelet preparation
Studies on human platelets were carried out with ethical
approval from the Central Oxford Research Committee (Ref:
C00:203), with written informed consent obtained from all donors.
Washed platelets were prepared from platelet rich plasma (PRP) in
the presence of prostacyclin (0.1 mg/ml) [25]. Blood was
resuspended in Tyrode’s-Hepes buffer (134 mM NaCl, 0.34 mM
Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20 mM Hepes,
5 mM glucose and 1 mM MgCl2, pH7.3). Animals were bred and
blood removed under an approved Home Office Licence. Blood
was drawn either by cardiac puncture or from the vena cavae of
terminally CO2-narcosed mice, originally anaesthetised with
gaseous isofluorane. Blood was taken into 100 ml ACD and
200 ml modified Tyrode’s-Hepes buffer. Platelets were prepared as
described [25], except final separation from PRP was by spinning
at 1,000 g for 6 min. They were resuspended at 2–5610
8/ml in
Tyrode’s-Hepes.
Platelet aggregation and spreading
Aggregation was performed at 37uC with constant stirring
(1200 rpm) in a Chronolog 490-2D aggregometer (Labmedics,
Manchester, UK) using 2610
8/ml platelets in a sample size of
300 ml. Secretion of ATP was measured using luciferase-luciferin
reagent. Platelet spreading was carried out as described [27].
Where indicated, apyrase (2.5 units/ml) and indomethacin
(10 mM) were added 60 sec before experimentation to prevent
the action of released ADP or formation of thromboxane A2,
respectively.
Flow Cytometry
Expression of the cell surface glycoproteins was measured by
flow cytometry [26].
Immunoprecipitation and western blotting
300 ml washed platelets (5610
8/ml) were stimulated under
stirring conditions (1200 rpm), terminated by addition of an equal
volume of ice-cold 2% NP-40 lysis buffer and immunoprecipita-
tions (IPs) carried out as previously described [28]. For PKCd, IPs
were carried out using monoclonal antibody against PKCd from
BD Pharmingen (clone 14) and resulting blots probed using anti-
PKCd antisera from Santa Cruz (sc-937). For PKCe, IPs and blots
were carried out using monoclonal antibody from BD Pharmingen
(clone 21). For PLCc2, Syk and Btk IPs, proteins were sequentially
immunoprecipitated from each sample, pre-clearing between each
IP [25]. Densitometry was analysed using Alpha Imager 220
Documentation and Analysis System Software.
Pleckstrin phosphorylation
Pleckstrin phosphorylation was monitored as described [29].
The levels of radioactivity in each band were measured using a
Phosphorimager SI (Molecular Dynamics) and ImageQuaNT
software, version 4.2a.
Aggregate formation on collagen under shear
Aggregate formation on collagen was carried out as described
[30] except that capillaries were imaged using differential
interference contrast optics on a Zeiss Axiovert 200M microscope
equipped with a Hamamatsu Orca 285 digital camera (Hama-
matsu Photonics UK Ltd, Herts, UK). Contents of capillaries were
subsequently lysed and levels of adherent platelets assessed by
probing for actin [26].
Statistical analysis of data
Unless stated otherwise, results are shown as mean6SEM.
Statistical significance of differences between two means was
determined by Student’s unpaired T-test or one-way ANOVA. If
means were shown to be significantly different, multiple
comparisons were performed by the Tukey test. Probability values
of P,0.05 were selected to be statistically significant.
Results
Comparison of novel PKC isoforms in human and mouse
platelets
In human platelets we were able to confirm expression of PKCd
and h, but not PKCe and g even though the antibodies detect
expression of these two isoforms in other tissues and cell lines
including human HeLa cells (Figure 1 and not shown). We were
also unable to detect expression of PKCe in human platelets
following attempts to concentrate the protein by immunoprecip-
itation (not shown). In contrast, mouse platelets express PKCd, e
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expression of PKCd in human platelets and rat cerebrum using an
antibody to rodent PKCd but this isoform was hard to detect in
mouse platelets. Thus, these results suggest that human platelets
robustly express PKCd but not PKCe, whereas mouse platelets
express higher levels of PKCe and lower levels of PKCd. There is
precedent for protein isoforms to show species-specific expression
between mouse and human platelets, with the PAR1 receptor
being the principle thrombin receptor in human platelets, whereas
it is absent in mouse platelets. In view of the apparent reciprocal
relationship between PKCd and PKCe, we focussed our studies on
these two isoforms in mouse and human platelets.
Investigation of tyrosine phosphorylation of PKCd and
PKCe
There are several reports of robust tyrosine phosphorylation of
PKCd in human platelets, confirmed in the present study using
thrombin and the two GPVI-specific agonists, convulxin and
CRP. In human platelets, tyrosine phosphorylation induced by
thrombin and convulxin is rapid but transient, returning to near
basal levels by 90 sec. Interestingly, in both cases, tyrosine
phosphorylation of PKCd is sustained in the presence of the
general PKC inhibitor, Ro 31-8220, demonstrating that it is under
feedback regulation from PKC, although the responsible isoform(s)
is not known (Fig 2A&B).
To address the functional significance of tyrosine phosphoryla-
tion of PKCd in platelets, we used the Src family kinase inhibitor
PP2 to inhibit tyrosine phosphorylation of PKCd (Fig 3A) [11,13].
PP2 had no significant effect on phosphorylation of the major
PKC substrate in platelets, pleckstrin, by a sub-maximal (0.1 unit/
ml) or maximal (1 unit/ml) concentration of thrombin, although
phosphorylation was completely inhibited by the pan-PKC
inhibitor, Ro 31-8220 (Fig 3B and not shown). These results
demonstrate either that pleckstrin is not significantly phosphory-
lated by PKCd in human platelets or that tyrosine phosphorylation
of PKCd does not significantly alter its activity.
In contrast, in mouse platelets thrombin stimulated a rapid, but
sustained increase in tyrosine phosphorylation of PKCd that was
unaltered in the presence of Ro 31-8220, whereas the GPVI-
specific agonist CRP had no significant effect on tyrosine
phosphorylation of the novel isoform either on its own or in the
presence of the PKC inhibitor (Fig 3C). These results demonstrate
that regulation of PKCd phosphorylation in mouse platelets is
distinct from that in human platelets. Some constitutive phos-
phorylation of PKCe was observed in mouse platelets, which was
not altered upon stimulation by CRP or thrombin (Fig 3D),
consistent with neither agonist regulating PKCe through tyrosine
phosphorylation.
Functional studies on PKCe
2/2 mouse platelets
As mouse platelets lacking PKCd show increased aggregation in
response to collagen, we investigated responses in platelets lacking
PKCe. There was no significant difference in the number or size of
mouse platelets in PKCe-null mice relative to controls (not shown),
consistent with the report of no change in the profile of blood cells
Figure 1. Presence of novel PKC isoforms in human and mouse
platelets. Washed human (Hu) or mouse (Mo) platelets were lysed and
samples separated by SDS-PAGE. The resulting membranes were
blotted with antibodies raised against each isoform. Alongside each
sample, the positive control (+) was run, as recommended by the
antibody manufacturer. The results are representative of three
experiments.
doi:10.1371/journal.pone.0003793.g001
Figure 2. Effect of Ro 31-8220 (Ro) on PKCd tyrosine
phosphorylation. Human washed platelets in the presence of apyrase
(2.5 U/ml) and indomethacin (10 mM) were treated with (A) 1 U/ml
thrombin or (B) 3 mg/ml convulxin in the presence or absence of Ro 31-
8220 (10 mM, 1 min) for the times shown. Immunoprecipitations and
reprobes were carried out as in the methods. Histograms show mean
density of bands, normalised according to the basal value. *signifies
statistically significant from basal,
#signifies statistically significant from
equivalent time point without inhibitor. Data is from 3 separate
experiments.
doi:10.1371/journal.pone.0003793.g002
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PLoS ONE | www.plosone.org 3 November 2008 | Volume 3 | Issue 11 | e3793Figure 3. (A) Effect of PP2 on PKCd tyrosine phosphorylation. Human washed platelets were treated with 0.1 or 1 U/ml thrombin for 1 min in
the presence or absence of PP2 (10 mM, 5 min). Immunoprecipitations and reprobes were carried out as described in the methods. Histogram shows
mean density of bands, normalised according to the basal value. (B) Effect of PP2 on pleckstrin phosphorylation in thrombin-stimulated
platelets. Washed human platelets were labelled with radioactive
32P-orthophosphate and stimulated with 1 U/ml thrombin for 1 min. PP2 (10 mM,
5 min) or Ro31-8220 (10 mM, 1 min) were added where indicated. After separation by SDS-PAGE, the resulting gel was analysed using a
phosphoimager to obtain radioactivity levels. Histogram shows the level of pleckstrin phosphorylation compared to basal levels. Data from one
experiment, representative of two. (C) Tyrosine phosphorylation of PKCd in mouse platelets. Washed mouse platelets were stimulated with
PKC Isoforms in Platelets
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detect no expression of PKCe in platelets purifed from the null
mice, and could find no evidence for compensatory changes in
expression levels of other isoforms in platelets by western blot
(Fig 4). This is consistent with previous reports of no alterations in
expression of other isoforms in brain tissue from PKCe-deficient
mice [21].
Aggregation and dense granule secretion were investigated in
PKCe-null platelets using light-scattering aggregometry and
luciferin-luciferase luminescence, respectively. The PKCe-null
platelets showed a minor delay in the onset of aggregation and a
minor reduction in dense granule secretion to concentrations of
thrombin (0.03 units/ml) and PAR4 peptide (100 mM) that
induces near maximal aggregation in litter-matched control
platelets (Fig 5A and not shown). The impairment in response
was associated with a slight increase in shape change, which can be
explained by the delay in onset of aggregation which has an
opposing effect on light transmission. These observations suggest
that PKCe makes a minor contribution, alongside other PKC
isoforms, to aggregation and secretion mediated through the
PAR4 receptor. Consistent with this, there was no significant
change in aggregation to ADP (not shown), which induces platelet
aggregation independent of PKC [31].
In contrast, there was a more marked reduction in the onset of
aggregation and level of ATP secretion to low and intermediate
concentrations of collagen and the GPVI-specific ligand, CRP
(Fig 5A). A full recovery in aggregation, although not secretion,
was seen at higher concentrations of CRP and collagen (Fig 5A
and not shown). However, there was no defect in spreading of
PKCe-null platelets on collagen, immobilised fibrinogen or
thrombin (Fig 5B). The levels of the two collagen receptors, GPVI
and a2b1, and the major platelet integrin, aIIbb3, were similar in
the PKCe-null and litter-matched control platelets (Fig 5C). These
results demonstrate a selective impairment in platelet activation
through the GPVI collagen receptor which is not the result of an
alteration in receptor expression.
Protein phosphorylation in PKCe
2/2 mouse platelets
The molecular basis of the reduced response was investigated by
measurement of pleckstrin phosphorylation, revealing a marked
reduction downstream of CRP whereas there was only a small
decrease in response to thrombin in PKCe-null platelets compared
to littermate controls (Fig 6A). This reduction in response to GPVI
was associated with a marked decrease in tyrosine phosphorylation
induced by the agonist, illustrated by measurement of phosphor-
ylation in whole cell lysates (Fig 6B). The FcRc-chain runs as a
distinct band in the whole cell lysate and, importantly, its
phosphorylation can be seen to be reduced revealing that
inhibition occurs at a proximal stage in the signalling cascade.
Consistent with this, immunoprecipitation studies reveal reduced
tyrosine phosphorylation of several other signalling proteins that
lie downstream of the FcRc-chain in the GPVI signalling cascade,
namely Syk, Btk and PLCc2 (Fig 6C). These results therefore
identify a role for PKCe in the GPVI signalling pathway that is
mediated by a reduction in phosphorylation of the FcRc-chain
underlying the selective defect in response to collagen and CRP.
Consistent with this, a pan PKC inhibitor, Ro 31-8220, reduces
CRP-stimulated tyrosine phosphorylation in whole cell lysates (not
shown) and of the FcRc-chain and Syk in Syk immunoprecipitates
in mouse platelets (Fig 6D), although interestingly a similar effect is
not seen in human platelets (not shown).
Platelet aggregation under arteriolar shear in PKCe
2/2
mouse platelets
The consequence of the defect in GPVI receptor signalling on
aggregate formation on a collagen surface at arteriolar shear was
investigated. Blood from control and PKCe
2/2 mice rapidly
forms platelet aggregates on collagen, which continue to increase
in size over the course of several minutes, with no discernable
difference in either population (Fig 7A). Consistent with this, there
was no significant difference in surface area coverage (Fig 7B) or
the level of platelet protein as measured by western blotting for
actin (not shown). The lack of an effect on platelet aggregation
under arteriolar flow in the absence of PKCe is consistent with
previous reports of unaltered aggregate formation on collagen
under similar conditions in mice that have a reduced level of the
GPVI-FcRc-chain complex, despite the partial reduction in
aggregation to collagen [26]. This is presumably because the
inhibition of the response to collagen is partial and aggregate
growth under arteriolar shear is driven by the secondary mediators
ADP and TxA2.
Discussion
The present study demonstrates a selective role for PKCe in
GPVI signalling in mouse platelets with impaired aggregation and
secretion to collagen and CRP. In comparison, aggregation and
secretion induced through the PAR4 receptor are only marginally
inhibited, consistent with a minor role for this PKC isoform in
Figure 4. Expression of PKC isoforms in PKCe-null platelets.
Platelets were prepared from PKCe-deficient mice (PKCe2/2) and wild-
type littermate controls (WT) and equal protein amounts of whole cell
lysates analysed by western blot, using antisera specific for individual
PKC isoforms, PKC e, a, d and h, as indicated.
doi:10.1371/journal.pone.0003793.g004
3 mg/ml CRP or 1 U/ml thrombin in the absence or presence of Ro31-8220 (10 mM, 1 min) (left), or with 1 U/ml thrombin for the times shown (right)
in the presence of apyrase (2.5 U/ml) and indomethacin (10 mM). Immunoprecipitations and reprobes were carried out as described in the methods.
Histogram shows mean density of bands, normalised according to the basal value. (D) Tyrosine phosphorylation of PKCe in mouse platelets.
Washed mouse platelets were stimulated with 3 mg/ml CRP or 1 U/ml thrombin for 1 min. Immunoprecipitations and reprobes were carried out as
described in the methods. All studies described in this figure were performed in the presence of apyrase (2.5 U/ml) and indomethacin (10 mM).
Histograms show mean density of bands, normalised according to the basal value: *signifies values significant from basal,
#signifies significant from
equivalent time point without inhibitor. Data is from 3 separate experiments.
doi:10.1371/journal.pone.0003793.g003
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defect in GPVI signalling in PKCe-deficient platelets contrasts
sharply with that of PKCd, as platelets from mice deficient in the
latter show increased filopodia formation on CRP and increased
aggregation to collagen in suspension [20]. This demonstrates
unique functions for the two novel PKC isoforms downstream of
GPVI in mouse platelets. The defect in GPVI signalling seen in
the PKCe-null mouse platelets is not due to a change in the level of
expression of GPVI or a2b1. The observation that aggregation to
ADP was not altered in mouse platelets argues against a role for a
change in expression of integrin aIIbb3, a result confirmed by flow
cytometry.
Figure 6. (A) Pleckstrin phosphorylation in PKCe-null platelets. Washed platelets from PKCe-deficient (PKCe
2/2) mice or wild-type (WT)
littermate controls labelled with radioactive
32P-orthophosphate were stimulated in the presence of apyrase (2.5 U/ml) and indomethacin (10 mM)
with 0.1 U/ml thrombin or 0.3 mg/ml CRP for 1 min. After separation by SDS-PAGE the resulting gel was analysed using a phospho-imager to obtain
radioactivity levels. The level of pleckstrin phosphorylation is shown in a histogram with values normalised to basal levels. B) Whole cell tyrosine
phosphorylation in PKCe
2/2 platelets. Washed platelets from PKCe
2/2 or WT littermate controls were stimulated for 60 sec with 1 or 3 mg/ml
CRP before lysis. SDS-PAGE gels were run as described in the methods. The arrow shows position of the FcR c-chain. (C) Tyrosine
phosphorylation downstream of GPVI in PKCe-null platelets. Washed PKCe
2/2 or WT platelets were stimulated for 60 sec with 0.3 mg/ml
CRP. Immunoprecipitations and reprobes were carried out as described in the methods. (D) The effect of Ro31-8220 on tyrosine
phosphorylation in CRP-stimulated mouse platelets. Washed WT platelets were pre-incubated with (Ro) or without (2) Ro 31-8220 (10 mM,
1 min) prior to harvesting without (B) or with stimulation for 60 sec with 1 mg/ml CRP. Syk was immunoprecipitated and western blotted for
phosphotyrosine as described in the methods. The location of Syk and the coprecipitated FcR c-chain are shown. For all the above, results are
representative of between 2–5 experiments.
doi:10.1371/journal.pone.0003793.g006
Figure 5. Platelet function in PKCe-null mice. (A) Aggregation and ATP secretion. Washed platelets from PKCe-deficient (PKCe
2/2) mice or
wild-type (WT) littermate controls were stimulated with the indicated concentrations of CRP, collagen or PAR4 peptide. Aggregation and dense
granule secretion were investigated using light-scattering aggregometry and luciferin-luciferase luminescence, respectively. Traces are representative
of between 3–7 mice. (B) Spreading. PKCe
2/2and wild-type (WT) washed platelets in the presence of apyrase (2.5 U/ml) and indomethacin (10 mM)
were exposed to surfaces of 100 mg/ml fibrinogen (FG), 1 U/ml thrombin (Thr), or 100 mg/ml collagen (COLL) for 45 min before fixing and mounting.
Representative images from each condition are shown. Histograms depict levels of platelet adhesion to each surface and platelet mean surface area
(spreading). The results are from one experiment that is representative of three. (C) Expression levels of surface glycoproteins. PKCe
2/2 and WT
washed platelets were incubated with FITC-labelled antisera against (upper panels) GPVI and integrin aIIbb3 and (lower panels) integrin a2b1 and
expression levels analysed by flow cytometry. The shaded area represents the signal from non-specific IgG control.
doi:10.1371/journal.pone.0003793.g005
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decrease in tyrosine phosphorylation at a proximal stage of its
signalling cascade, as phosphorylation of the FcRc-chain and Syk
are reduced. A mechanism to explain this has been described in
mast cells, where, in response to activation of the FceRI receptor,
PKC phosphorylates the FcRc-chain on threonine-60, two
residues downstream of the conserved C-terminal tyrosine residue
which is phosphorylated in the ITAM, leading to Syk association
[32]. Expression of a mutated form of the FcRc-chain with
threonine-60 replaced by alanine led to reduced association and
activation of Syk and subsequent inhibition of degranulation in
response to IgE [33]. The authors speculate that phosphorylation
of the ITAM by a novel PKC isoform increases binding of Syk to
the ITAM and enhances activation, illustrated by the increase in
tyrosine phosphorylation of Syk and downstream proteins. We
speculate that this increase in binding of Syk to the FcRc-chain
protects the ITAM moiety from dephosphorylation leading to a
net increase in tyrosine phosphorylation. In mast cells, PKCd is
responsible for the phosphorylation. However, although PKCd is
expressed robustly in human platelets, it is at low levels in mouse
platelets. PKCe is present in mouse platelets and, as for PKCd, its
recombinant form does mediate phosphorylation of the FcRc-
chain ITAM in vitro [32]. Tyrosine phosphorylation of the FcRc-
chain, Syk and downstream proteins is also reduced in the
presence of a pan-PKC inhibitor in mouse platelets, confirming
that the reduction in tyrosine phosphorylation of FcRc-chain is
mediated by the loss of a PKC isoform. Interestingly, a similar
result is not seen in human platelets, which, although consistent
with the low levels of PKCe, is surprising given the presence of
PKCd. This may reflect a further difference between mouse and
human platelets in the role of novel PKC isoforms.
Our inability to detect expression of PKCe in human platelets
was not expected as there are several reports describing its
presence. However, Buensuceso et al. were also unable to detect
expression of PKCe in human platelets although both positive and
negative studies used the same source of antibodies as used in the
present one [11,14,16,17]. Our attempt to address this through
concentration of PKCe by immunoprecipitation was unsuccessful.
Whilst the explanation for this discrepancy is not known, and may
reflect differences in batches of antibodies, the cumulative reports
illustrate that PKCe is either absent in human platelets or present
at a very low level.
The present study demonstrates that the tyrosine phosphoryla-
tion of PKCd seen in human platelets is down-regulated through a
PKC-dependent pathway. The molecular basis of this is not
known, although it could be dependent upon the direct or indirect
regulation of a protein tyrosine phosphatase. For example the
SHP-1 tyrosine phosphatase interacts with PKCa and is
phosphorylated on a consensus PKC phosphorylation site
following human platelet activation [34]. Phosphorylation of
SHP-1 negatively regulates its activity in vitro, but the in vivo
consequences of phosphorylation may be more complex, with the
potential to regulate substrate specificity and localisation. Inter-
estingly, in mouse platelets tyrosine phosphorylation of PKCd is
sustained, further emphasising the species-specific functions and
regulation of PKC isoforms. PAR4 has been reported to stimulate
sustained tyrosine phosphorylation of PKCd in human platelets
[13], and this is the major signalling receptor for thrombin in
mouse platelets. Thus, the difference in kinetics may reflect
differential expression and roles of PAR1 and PAR4 in human and
mouse platelets.
Although frequently used as a marker of PKCd activation, the
functional significance of its tyrosine phosphorylation is unclear. It
has been reported to increase the kinase activity of PKCd in
human platelets but is not required for membrane association [12].
This study shows that blockade of Src kinases, and hence
phosphorylation of PKCd, does not alter pleckstrin phosphoryla-
tion in thrombin-stimulated platelets, arguing against direct
regulation of enzymatic activity, with the caveat that PKCd may
not play a major role in regulating pleckstrin phosphorylation. The
lack of Src kinase blockade on pleckstrin phosphorylation is
consistent with the fact that Src kinases play a minimal role in
thrombin-induced platelet aggregation [35], again questioning the
significance of PKCd tyrosine phosphoryation in this signalling
pathway. The significance of tyrosine phosphorylation of PKCd
downstream of GPVI remains to be established.
In conclusion, the present study has provided further evidence
for specific regulation and functions of PKC isoforms by focussing
on the two novel PKCs, PKCd and PKCe, and in particular has
shown that PKCe plays a critical role in potentiating the proximal
events in the GPVI signalling pathway. Further, it has also
demonstrated differences in expression and phosphorylation of the
two isoforms in mouse and human platelets further revealing
species-specific functions of individual isoforms.
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